Data Monitoring Committee Gives 'Go Ahead' in the MIV-711 Osteoarthritis Extension Study

PR Newswire |

STOCKHOLM, /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the independent Data Monitoring Committee (DMC) has again recommended continuation of the MIV-711 osteoarthritis extension study without modifications based on a review of the accumulated safety data.

As part of the MIV-711 phase IIa programme, an independent DMC is periodically scheduled to review the accumulated safety data. Based on the present DMC review of all safety data, including unblinded data from the initial study and data to date from the extension study, the DMC has recommended that the extension study should go ahead as planned. This most recent review constitutes the sixth and final planned DMC review during the phase II programme.

"We are encouraged that the overall assessment so far indicates an acceptable safety profile for MIV-711 and look forward to reporting the headline efficacy data from the initial randomized blinded study later this month," says John Öhd, CMO at Medivir.

About MIV-711

MIV-711 is being developed to slow or reverse the progressive degeneration of joints affected by osteoarthritis, and is therefore referred to as a Disease Modifying Osteoarthritis Drug (DMOAD). Since there are no DMOADs approved for use currently, the standard of care for osteoarthritis patients is based on changes in life style and the use of analgesics. The long-term use of analgesics by osteoarthritis patients is associated with an increased risk of side effects such as gastrointestinal bleeding and opioid dependency. DMOADs therefore represent a very large and attractive market opportunity. Medivir estimates that the US market alone is greater than USD 6 billion annually for a drug that impacts disease progression, even if its use was restricted just to patient populations with moderate osteoarthritis in weight-bearing joints.



For further information, please contact:
Anders Lundin, Interim CFO Medivir AB, mobile: +46(0)731-251-453
John Öhd, CMO Medivir AB, mobile +46(0)725-296-200

Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on .

About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/medivir/r/data-monitoring-committee-gives--go-ahead--in-the-miv-711-osteoarthritis-extension-study,c2346448

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/data-monitoring-committee-gives-go-ahead-in-the-miv-711-osteoarthritis-extension-study-300519514.html

SOURCE Medivir

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Taranis Resources Inc.

Taranis Resources Inc is an exploration stage company. The Company along with its subsidiaries is engaged in the acquisition and exploration of mineral properties. Its projects include Thor Property in…

Private Markets

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…